


ALS and the Search for Hope: What the Biology Can Teach Us

Exploring Inflammation, Hormonal Health, and Mitochondrial Support



(C) 2026 Millennium Health Centers, Inc.
Dr. Mark L. Gordon

ALS and the Search for Hope: What the Biology Can Teach Us

Exploring Inflammation, Hormonal Health, and Mitochondrial Support

Abstract

An ALS diagnosis brings difficult questions for patients and families: Why is this happening, what is damaging the nerves, and could understanding that damage reveal additional ways to help? This article explores the connections between trauma, persistent neuroinflammation, hormonal health, and mitochondrial function as a framework for understanding motor-neuron vulnerability and investigating treatment possibilities.

The trauma-related statistics discussed in the original article warrant attention. A systematic review and meta-analysis reported **51% higher odds of ALS among people with a history of trauma** compared with those without that history (odds ratio 1.51; 95% confidence interval 1.32–1.73). Trauma within five years before diagnosis was associated with **84% higher odds** (odds ratio 1.84; 95% confidence interval 1.56–2.17). [35] These associations do not establish that trauma caused ALS or indicate what proportion of cases resulted from injury. More recent population research raises the possibility that early, unrecognized ALS can itself increase susceptibility to injury. [2]

The biological discussion examines how cellular injury and inflammatory signaling may interact with oxidative stress, excessive excitatory signaling, and impaired energy production. Within this framework, the Millennium Protocol is explored through individualized hormonal replenishment when deficiencies are documented and nutraceutical use intended to decrease inflammation and oxidative stress. Semax, SS-31, and MOTS-c are considered for their experimental effects on neuronal-support signaling, mitochondrial protection, and metabolic adaptation, respectively. [3–5]

These findings provide reasons for investigation, rather than proof that the proposed combination slows or reverses human ALS. The aim is to help patients and families understand the biology, evaluate emerging possibilities, and participate in informed discussions alongside established ALS care. Meaningful progress requires translating plausible mechanisms into carefully tested improvements in function, quality of life, and survival.

1. Introduction: Looking Beyond the ALS Diagnosis

When ALS enters a family's life, it changes more than movement. It changes routines, expectations, and conversations about the future. Patients and loved ones begin searching for answers, not simply to understand the diagnosis, but to discover whether there are additional ways to preserve function, support health, and improve daily life. That search deserves compassion, scientific honesty, and a willingness to investigate possibilities carefully.

ALS affects the motor neurons that carry instructions from the brain and spinal cord to the muscles. Understanding why these cells become damaged requires looking beyond the neurons themselves. Their survival depends on neighboring support cells, a stable chemical environment, and the energy needed to maintain their complex functions. Research has shown that inflammatory activity in surrounding immune cells can contribute to motor-neuron death in experimental ALS, suggesting that the environment around a neuron can influence its survival.

This brings us to **neuroinflammation**, the inflammatory response within the brain and spinal cord. Inflammation is part of the body's protective machinery. The central question is what happens when that response persists, becomes poorly regulated, or interacts with other sources of cellular stress. Could an initially protective process become one of the mechanisms sustaining neurological damage? And, if so, could addressing that process provide additional opportunities for treatment?

Physical trauma is one possible starting point worth examining. However, the relationship between trauma and ALS remains unsettled. A large population study found that the increased rate of ALS diagnosis following traumatic brain injury was concentrated within the first two years after injury. The investigators suggested that early, unrecognized ALS might sometimes increase susceptibility to falls or injuries, a possibility known as reverse causation. These findings caution against assuming that an injury caused ALS simply because it occurred before diagnosis.

The approach explored in this article therefore asks a broader question: **Which biological processes might be contributing to ongoing damage, and which of those processes could potentially be modified?** Within that framework, the Millennium Protocol's hormonal replenishment and nutraceutical components are examined as proposed ways to address documented deficiencies and support inflammatory regulation. Correcting a deficiency and changing the course of ALS are different outcomes; evidence for one does not establish the other.

We also examine Semax, SS-31, and MOTS-c as potential research tools and therapeutic candidates. Experimental findings connect Semax with neuroprotective and inflammatory signaling, SS-31 with mitochondrial protection, including research in an ALS mouse model, and MOTS-c with adaptation to metabolic stress. Their mechanisms raise useful questions, but they do not establish that these peptides, individually or together, benefit people living with ALS.

The purpose of this article is to make those questions understandable. It offers a biological rationale for investigation, without dosing recommendations or promises of recovery. These possibilities should be considered alongside established ALS care, with attention to both evidence and uncertainty.

For patients and families, hope does not require certainty. It requires meaningful possibilities, honest information, and a clear understanding of what is known, and what still needs to be tested.

2. How Trauma Can Start an Inflammatory Response

For a person living with ALS, looking back at an accident, sports injury, or military exposure can raise a difficult question: Could that experience have contributed to what is happening now? Biology offers ways to investigate this possibility. It cannot, by itself, determine why an individual developed ALS.

The first step is to understand how a physical force can become a biological disturbance.

From Mechanical Force to Cellular Injury

A nerve cell is a living structure with a delicate outer membrane and an internal framework. Its long extension, called an **axon**, carries electrical messages and transports materials needed to keep the cell functioning.

During a traumatic event, rapid stretching or deformation can disturb an axon's structure and the channels that regulate its electrical activity. This conversion of physical force into a cellular response is part of what scientists call **mechanotransduction**.

In laboratory experiments, stretching axons produced abnormal sodium entry, followed by increased calcium inside the axons. Calcium is essential for normal signaling, but its location and concentration must be tightly controlled. These experiments demonstrate how a brief mechanical event can trigger a chemical disturbance that continues after the force has ended. [6]

This distinction matters: the impact is the initial event, while some of the resulting injury develops through the cellular responses that follow.

Damaged Cells Send an Alarm

Injured cells can release molecules that alert the immune system to tissue damage. Scientists call these **damage-associated molecular patterns**, or DAMPs. Unlike an infection, this response can begin without bacteria or viruses.

One example is **HMGB1**, a protein normally involved in organizing DNA inside cells. When released outside injured cells, it can act as a danger signal. Experimental traumatic brain injury research has linked HMGB1 to activation of a receptor called TLR4 and to inflammatory communication between neurons, microglia, and astrocytes. Microglia are the nervous system's resident immune cells; astrocytes are support cells that help maintain the environment around neurons. [7]

The resulting response is initially an attempt to protect tissue and manage damage. Understanding how that response is regulated, and how it eventually resolves, is central to understanding recovery.

Why Repeated Exposures Deserve Attention

An injury does not always produce an immediate, obvious structural change. In a laboratory model, mild stretching altered sodium-channel expression in axons that initially showed no overt damage. A subsequent stretch then produced a greater disturbance in calcium regulation and more injury. [8]

This finding provides a biological reason to study repeated exposures and the time between them. It does not establish that every minor impact causes lasting damage, or that repeated impacts inevitably lead to ALS. The experiment examined cultured axons, rather than the long-term health of people.

Can the Response Outlast the Injury?

Human tissue research shows that inflammatory changes can persist long after some traumatic brain injuries. In one postmortem study, a subset of people who survived more than a year after injury had reactive microglia and evidence of ongoing damage to white matter, the tissue containing the brain's connecting nerve fibers. Such inflammatory changes were observed as long as 18 years after trauma. [9]

These observations do not prove that inflammation caused the continuing damage. Inflammation could be responding to degeneration, contributing to it, or participating in both processes. They also should not be generalized to every concussion or minor exposure.

For this article, the significance is that **a mechanical injury can initiate biological responses that extend beyond the moment of impact**. The next question is how a protective response might become persistent and potentially harmful. Examining that transition will help us understand why inflammatory pathways are being investigated as possible targets in neurodegenerative disease.

3. When Protective Inflammation Becomes Persistent

After an injury, the nervous system must recognize damaged tissue, remove debris, and support repair. Inflammation helps coordinate these tasks. The difficulty arises when inflammatory activity continues alongside ongoing damage, creating an environment that becomes increasingly stressful for surviving neurons.

For patients and families, this distinction matters. The biological goal is to preserve useful immune functions while reducing the responses that contribute to injury.

Microglia: A Protective Response That Can Become Harmful

Microglia monitor conditions within the brain and spinal cord. After injury, they respond to cellular danger signals and help manage damaged tissue. However, their activity can remain altered long after the initial event.

In an experimental mouse study, traumatic brain injury was followed by persistent microglial activation, oxidative activity, and progressive tissue damage over the following year. The findings linked chronic

inflammation with continuing degeneration, although an association alone cannot establish which process is driving the other. [10]

A useful way to understand this relationship is as a possible feedback loop: injured tissue stimulates immune activity, and some immune responses may impose additional stress on nearby tissue. Further injury can then provide new signals that sustain the response. Whether this loop develops, and how strongly it contributes to disease, depends on the biological setting.

Inflammatory Messages Can Change Neighboring Support Cells

Microglia communicate with other cells through chemical signals. Those messages can alter how neighboring astrocytes behave.

In a landmark experimental study, activated microglia released a combination of signals, IL-1 α , TNF, and C1q, that induced an astrocyte state with reduced supportive functions and the ability to harm neurons and oligodendrocytes, the cells that produce myelin. The investigators also identified markers of this astrocyte response in human neurodegenerative tissue, including ALS tissue. [11]

This does not mean that every activated astrocyte is harmful. It demonstrates that inflammatory communication can change the environment surrounding a neuron. A cell that normally contributes to neuronal health can, under particular experimental conditions, participate in damage.

The Inflammasome: An Amplifier Inside Cells

Another mechanism under investigation is the **inflammasome**, a protein complex that helps cells respond to danger. One form, called the **NLRP3 inflammasome**, can activate caspase-1, an enzyme involved in processing inflammatory signals such as IL-1 β and IL-18.

In a mouse model of traumatic brain injury, researchers used an experimental compound called MCC950 to inhibit NLRP3. Treatment reduced measures of inflammasome activity and injury and improved neurological outcomes. These findings support further investigation of this pathway; they do not establish the same benefit in people with ALS. [12]

The broader lesson is that inflammation consists of multiple interacting pathways. Identifying which pathways are active is more informative than treating inflammation as a single, uniform process.

Persistence Does Not Mean Inevitability

Long-lasting inflammatory activity has also been observed in some human brain-injury tissue, as discussed in the preceding section. However, those observations do not predict an individual's future or prove that trauma will lead to ALS. [9]

They help explain why researchers investigate the transition from an acute injury response to a persistent biological disturbance. The question is whether reducing harmful inflammatory signaling can protect vulnerable cells while allowing necessary repair to continue.

For ALS, this question has direct experimental relevance: research has shown that microglial NF- κ B signaling can contribute to motor-neuron death in an ALS model. [1] This provides a reason to study inflammatory regulation, while leaving the effectiveness of any proposed treatment to be demonstrated.

4. How Inflammation Can Contribute to Neurodegeneration

A motor neuron must maintain its electrical activity, produce energy, manage damaged proteins, and transport materials along its axon. These tasks are closely connected. A disturbance in one can place additional pressure on the others.

This helps explain why researchers examine ALS as a disease involving interacting biological processes. Inflammation may contribute to this interaction, while damage originating within neurons can also stimulate inflammation. The relationship can operate in both directions.

When Excitatory Signals Become Excessive

Glutamate is a chemical messenger that helps neurons communicate. After a message is delivered, surrounding cells must remove excess glutamate so that the signal ends appropriately.

A foundational study of human ALS tissue found a marked reduction in the glial glutamate transporter GLT-1, also known as EAAT2. This transporter helps clear glutamate from the space around neurons. Its loss provides a biological explanation for how glutamate regulation may become impaired in ALS. [13]

Excessive stimulation by glutamate can contribute to **excitotoxicity**, injury caused by overactivation of excitatory signaling. Calcium regulation is part of this process. As discussed earlier, traumatic axonal injury can also disturb calcium balance. [6] These are overlapping mechanisms, although finding an overlap does not establish that trauma initiated an individual's ALS.

For families, the useful distinction is that a chemical necessary for communication can become harmful when its signaling is excessive or poorly controlled.

Oxidative Stress and Mitochondrial Injury

Mitochondria supply much of the energy cells need to function. They also participate in cellular stress responses. Their health matters in neurons and in the support cells surrounding them.

In an experimental ALS study, astrocytes carrying the SOD1-G93A mutation had impaired mitochondrial function and increased oxidative and nitrosative stress. These astrocytes also promoted motor-neuron death in a cell-culture system. Treating the astrocytes with mitochondrial-targeted antioxidants improved their mitochondrial function and reduced their harmful effects on motor neurons. [14]

Oxidative stress occurs when reactive oxygen molecules exceed the capacity of cellular defenses to manage them. **Nitrosative stress** involves damaging reactions associated with reactive nitrogen molecules. In the study above, these disturbances linked the condition of a support cell's mitochondria to the survival of neighboring neurons.

This finding offers a reason to investigate mitochondrial protection. It remains an experimental observation, rather than proof that an antioxidant or peptide treatment changes human ALS progression.

Damaged Proteins Can Disrupt Cellular Transport

Proteins must maintain suitable shapes to perform their jobs. Changes in protein structure can interfere with cellular function, including the movement of materials within an axon.

A study examining SOD1 found that oxidized, otherwise normal SOD1 and ALS-associated mutant SOD1 could share abnormal structural features. In experimental transport assays, these altered proteins inhibited fast axonal transport, the system that moves essential materials along nerve fibers. [15]

This illustrates a potential connection between oxidative damage, altered protein structure, and impaired transport. It does not establish that SOD1 explains every form of ALS, or that inflammation is always the first event.

Why These Connections Matter

Taken together, these findings suggest several ways neuronal injury may become self-reinforcing. Impaired glutamate clearance can increase excitatory stress. Mitochondrial dysfunction in support cells can make the surrounding environment more harmful. Altered proteins can interfere with the transport needed to maintain an axon.

The proposed feedback loop is a framework for understanding these interactions, rather than a proven sequence that occurs identically in every patient. Its value is that it identifies distinct questions for treatment research: Can harmful inflammatory signaling be reduced? Can mitochondrial function be protected? Can the environment supporting motor neurons be improved?

These questions provide the biological foundation for the hormonal, nutraceutical, and peptide approaches discussed later. Demonstrating that an intervention affects one pathway, however, is only a first step. Meaningful benefit must ultimately be measured through outcomes that matter to people living with ALS.

5. Connecting These Processes to ALS

The preceding sections describe how injury, inflammation, and cellular stress can interact. To understand their relevance to ALS, we must ask a more specific question: Why do these processes damage particular motor neurons, while other cells remain relatively resistant?

The answer involves both the environment surrounding a neuron and the biology within it. This distinction helps explain why an inflammatory model can contribute to our understanding of ALS without accounting for every aspect of the disease.

Motor Neurons Do Not All Have the Same Vulnerability

ALS does not affect every motor-neuron population equally. Understanding the differences between vulnerable and resistant cells may reveal protective mechanisms worth investigating.

In one experimental study, researchers identified substantial differences in gene expression between motor-neuron populations. A protein called **matrix metalloproteinase-9**, or MMP-9, was associated with vulnerable fast motor neurons. Reducing its activity in mice carrying an ALS-associated SOD1 mutation delayed the loss of nerve connections to muscles. [16]

This finding illustrates an important principle: the same disease environment can affect different cells differently. A neuron's internal characteristics can influence how it responds to stress.

It also helps explain why reducing inflammation alone may be insufficient. The processes making a neuron vulnerable may include changes within the neuron itself.

Protein Abnormalities Are Part of the Disease

ALS research has identified characteristic abnormalities in proteins, including **TDP-43**. A foundational human tissue study identified TDP-43 as a major component of abnormal protein deposits in ALS and certain forms of frontotemporal degeneration. [17]

These findings provide evidence of disease biology that extends beyond inflammation. They raise questions about how cells handle proteins, how abnormal deposits develop, and how those changes interact with other sources of injury.

An inflammatory explanation must therefore be integrated with protein-related mechanisms. Finding inflammation in affected tissue does not, by itself, establish whether it began the disease, accelerated an existing process, or developed in response to damaged cells.

Genetic Causes Must Also Be Considered

Some forms of ALS have an identifiable genetic basis. For example, researchers discovered that an expanded repeating DNA sequence in **C9ORF72** can cause a form of ALS associated with frontotemporal degeneration. [18]

This is particularly relevant to the trauma hypothesis. A model of ALS must accommodate established genetic causes as well as possible environmental contributors. Trauma cannot be assumed to explain a disease simply because an injury occurred in a person's history.

Genetic findings do not make research into inflammation or mitochondrial function irrelevant. They do mean that proposed interventions must be evaluated within the biological context of the disease being treated.

Where Does Trauma Fit?

Trauma provides a plausible route to cellular injury and inflammatory activation, as the earlier sections describe. Establishing that it causes ALS in humans is a separate question.

The population study discussed in the introduction found that the increased rate of ALS diagnosis after traumatic brain injury was confined to the first two years following injury. The researchers considered the possibility that early, undiagnosed ALS increased the likelihood of injury. [2]

For patients and families, this means an injury history should be discussed thoughtfully rather than treated as a definitive explanation. It cannot determine an individual's cause of ALS or predict whether an anti-inflammatory approach will help.

From Understanding Disease to Testing Treatment

The biological rationale developed here is that **motor-neuron survival depends on interacting processes that may offer several targets for investigation**. Some relate to inflammatory support cells, others to proteins and genetic changes within cells, and others to the maintenance of cellular function.

The Millennium Protocol and the three peptides will be examined against this background. Their proposed roles must be matched to specific mechanisms, and their clinical value must be tested rather than inferred from those mechanisms.

For a family searching for options, this approach provides a useful question to bring to any proposed treatment: What evidence connects the intervention to the biology, and what evidence shows that it helps people?

6. Hormones and the Brain's Protective Environment

Hormones are chemical messengers that help coordinate the body's functions. Some also influence signaling within the nervous system and the way cells respond to stress. This raises an important question for people living with ALS: Could identifying and correcting hormonal deficiencies provide additional support?

To examine that possibility, we must distinguish three questions: Are hormone levels altered? Could those changes affect cellular function? Does replenishment improve symptoms or slow ALS progression? Each requires its own evidence.

How Inflammation Can Disturb Hormonal Signaling

The hypothalamus, a small region of the brain, helps regulate hormone production through communication with the pituitary gland. Inflammatory signals can interfere with this communication.

In an experimental rat study, the inflammatory molecules IL-1 β and TNF- α suppressed the release of gonadotropin-releasing hormone, or GnRH, and reduced the associated pituitary signal, luteinizing hormone. These findings demonstrate a mechanism through which inflammation can disrupt the reproductive hormone system. [19]

The study does not establish that this mechanism explains hormonal changes in every person with ALS. It provides a biological reason to investigate the relationship rather than assume that hormone levels and inflammation are unrelated.

What Has Been Observed in ALS?

A small human study reported lower free testosterone levels in people with ALS than in comparison participants. Free testosterone is the portion of circulating testosterone that is not bound to blood proteins. [20]

This observation raises a research question, rather than answering a treatment question. It does not show whether the difference preceded ALS, resulted from the illness, or contributed to progression. It also does not demonstrate that testosterone replacement protects motor neurons.

For an individual patient, the practical starting point is an assessment of symptoms and appropriately interpreted laboratory findings. ALS itself should not be treated as proof of a hormonal deficiency.

Neurosteroids and Inflammatory Regulation

Steroids produced within the nervous system are called **neurosteroids**. The broader term **neuroactive steroids** includes steroids that affect nervous-system function, whether produced locally or elsewhere in the body.

Pregnenolone is one steroid of interest. In laboratory research, it promoted the degradation of proteins involved in innate immune signaling and suppressed aspects of inflammatory activation. [21]

This suggests a possible interaction between steroid biology and inflammatory regulation. However, an effect in experimental cells does not establish that supplementation produces the same effect in the human spinal cord, or that it changes ALS outcomes.

The rationale for investigating hormonal support is therefore biologically meaningful, but its clinical effects must be evaluated separately.

Why Clinical Testing Matters

The experience with insulin-like growth factor-1, or IGF-1, illustrates this distinction. Despite a biological rationale and earlier research interest, a two-year randomized ALS trial found no benefit from the tested subcutaneous IGF-1 regimen. [22]

This result does not answer every question about hormonal health. It demonstrates why a plausible mechanism cannot substitute for clinical evidence.

Within the Millennium Protocol, the proposed role of hormonal replenishment is to address documented deficiencies through individualized assessment and monitoring. Any improvement in a deficiency-related symptom would be valuable, but it would remain distinct from evidence that ALS progression had slowed.

For patients and families, hormonal health represents an area that can be investigated carefully. The appropriate goal is to identify treatable problems, assess the effects of correcting them, and avoid assuming that a better laboratory value necessarily means better protection of motor neurons.

7. The Millennium Protocol: Hormonal Replenishment and Nutraceutical Support

The Millennium Protocol's proposed approach begins with a question: Are there measurable hormonal or nutritional problems that could be adding to a patient's burden of illness?

For someone living with ALS, this question can be meaningful even when correcting those problems does not change the underlying disease. The framework examined here combines individualized hormonal assessment with nutraceuticals intended to influence inflammation and oxidative stress. Its biological rationale must be considered separately from evidence of clinical effectiveness.

Hormonal Replenishment: Addressing Documented Deficiencies

As discussed in the preceding section, hormones can interact with inflammatory signaling, and hormonal differences have been reported in ALS. Within this framework, replenishment would be considered when assessment identifies a clinically meaningful deficiency.

The purpose is to investigate and address a potentially treatable problem. Treatment decisions require more than a single laboratory result: symptoms, repeat testing when appropriate, medical history, and the risks of replacement all matter.

Pregnenolone's effects on innate immune signaling provide one experimental rationale for studying steroid-related inflammatory regulation. [21] However, this finding does not establish that replacing pregnenolone, or another hormone, slows ALS. The same distinction applies to testosterone: identifying a deficiency and demonstrating a disease-modifying treatment effect are separate tasks.

Nutraceuticals: Matching Ingredients to Biological Targets

Nutraceuticals are nutrients or other biologically active compounds used with the intention of supporting health. In the Millennium framework, their proposed targets include inflammatory signaling, oxidative stress, and mitochondrial function.

Omega-3 fatty acids offer one example. In an experimental traumatic brain injury study, supplementation reduced inflammatory activity associated with the HMGB1/TLR4/NF- κ B pathway discussed earlier. [23] This supports a mechanism worth investigating, but it was an injury study rather than a clinical ALS trial.

Coenzyme Q10, or CoQ10, has attracted interest because of its roles as a mitochondrial cofactor and antioxidant. Yet an ALS phase II trial found insufficient evidence of benefit to justify proceeding to a larger phase III trial. [24] This result is important when explaining why supporting an energy-related pathway does not necessarily improve disease outcomes.

These examples show why each ingredient needs its own evidence assessment. Combining compounds with plausible mechanisms does not automatically establish that their effects are complementary, synergistic, or clinically beneficial.

A Nutrient-Related Intervention With Human ALS Evidence

Methylcobalamin, a form of vitamin B12, illustrates the value of testing a specific intervention in a defined patient population.

A randomized trial in Japan found that an ultrahigh-dose injectable methylcobalamin regimen slowed functional decline over 16 weeks in selected patients with early-stage ALS and a moderate rate of progression. [25]

This finding deserves attention, but its boundaries matter. It does not establish equivalent benefits from ordinary oral B12 supplements, nor does it validate a broader nutraceutical combination. The formulation, route, patient selection, and outcomes studied are part of the evidence.

A New Tool for Monitoring Inflammatory Activity

The Millennium-iXpressGenes inflammatory testing panel offers an additional way to follow inflammation-related activity. It measures gene-expression signals associated with pro-inflammatory cytokines, anti-inflammatory responses, and other pathways involved in cellular stress and repair. This can help identify both signals that promote inflammation and the body's efforts to regulate it.

Repeating the panel during treatment may help clinicians track changes in these signals alongside symptoms and functional assessments. The results provide additional biological information; they do not directly measure inflammation within the brain or spinal cord, and improvement in the panel alone does not establish that ALS progression has slowed.

What Would Count as Meaningful Benefit?

Evaluating this approach requires tracking how the patient is doing, alongside laboratory measurements. Improvements in a hormone level or an inflammatory marker cannot, by themselves, demonstrate protection of motor neurons.

The central questions are whether an intervention improves a relevant symptom, supports daily function, creates adverse effects, or changes the rate of decline. These outcomes should be assessed with the ALS care team, with clear goals established before treatment begins.

The Millennium Protocol's hormonal and nutraceutical components therefore represent an individualized supportive framework and a hypothesis for further study. The evidence discussed here does not demonstrate that the combined protocol slows or reverses ALS.

Its proposed biological targets help set the stage for examining Semax, SS-31, and MOTS-c. Each peptide will be assessed through the same sequence: what it does experimentally, how that mechanism might relate to ALS, and what remains unproven in patients.

8. Semax: Exploring Neuronal Support

For patients and families considering emerging approaches, the first question about a peptide is straightforward: What might it do, and how does that relate to ALS?

Semax is a synthetic peptide, a short chain of seven amino acids, studied for its effects on nervous-system signaling. The research examined here focuses primarily on experimental cerebral ischemia, where blood supply to part of the brain is interrupted. These studies provide a rationale for investigating neuronal protection, but they do not demonstrate that Semax treats ALS.

Supporting the Signals That Help Neurons Survive

Neurons respond to proteins called **neurotrophins**, which participate in cellular maintenance, survival, and adaptation. Examples include brain-derived neurotrophic factor, or BDNF, and nerve growth factor, or NGF.

In a rat model of cerebral ischemia, Semax increased the transcription of several neurotrophin and receptor genes. The effects differed according to the gene and the time after injury. [26]

Transcription is the production of RNA instructions from DNA. Increasing those instructions suggests an effect on a biological pathway, but it does not automatically establish greater protein activity, lasting neuronal protection, or functional recovery.

For ALS, the theoretical question is whether influencing supportive signaling could help vulnerable motor neurons withstand stress. That question requires direct investigation in ALS models and patients; findings in injured rat brain tissue cannot answer it alone.

Influencing Inflammatory Communication

Semax has also affected inflammatory signaling in experimental brain injury.

In a study of rats undergoing cerebral ischemia followed by restoration of blood flow, Semax reduced RNA transcripts associated with several inflammatory mediators, including IL-1 α , IL-1 β , IL-6, and selected chemokines. Chemokines are signals involved in directing immune-cell activity. [27]

However, Semax should not be described as simply switching inflammation off. An earlier rat study found broader changes in immune-related gene expression, including increases in some chemokine and immunoglobulin genes. [28]

Together, these findings suggest that its effects depend on the injury model, timing, and pathway being measured. Understanding that context matters because protective immune activity and harmful inflammatory activity can coexist.

From Gene Expression to Protein Signaling

The Semax study cited in the introduction examined proteins involved in cellular stress and recovery. In a rat ischemia-reperfusion model, researchers observed changes involving CREB, a regulator of gene expression, alongside reductions in selected signals associated with inflammation and cell death. [3]

These results strengthen the rationale for studying Semax beyond a single inflammatory marker. They remain findings from an experimental stroke model, rather than evidence that Semax preserves motor function or respiratory function in ALS.

Its Proposed Place in the Combined Approach

Within this article's treatment hypothesis, Semax would be investigated for its influence on neuronal support and inflammatory signaling. This could potentially complement approaches directed toward hormonal deficiencies or mitochondrial stress.

Complementary mechanisms are a reason to test a combination, rather than proof that the combination works. The studies discussed here do not establish synergy between Semax, hormonal replenishment, nutraceuticals, SS-31, and MOTS-c.

The important unanswered questions include whether Semax produces relevant effects in the motor pathways affected by ALS, whether those effects persist, and whether they translate into meaningful clinical benefit. Safety and interactions in the proposed combination also require evaluation.

For patients and families, Semax represents a research possibility grounded in experimental biology. Its potential value will depend on demonstrating that its biological effects help people with ALS, rather than assuming that neuroprotective findings in another condition will transfer unchanged.

9. SS-31: Exploring Mitochondrial Protection

Motor neurons depend on a continuous supply of energy to maintain their electrical activity and cellular functions. When examining ways to protect them, the mitochondria, the structures that produce much of that energy, are an important research target.

SS-31 is a synthetic peptide containing four amino acids. Its proposed contribution to the approach discussed here is mitochondrial protection. Laboratory research has examined how it interacts with mitochondrial membranes, and an experimental ALS study has tested whether it can improve motor performance and survival.

Protecting the Machinery That Produces Energy

The inner mitochondrial membrane contains the machinery used to produce **ATP**, a molecule that supplies usable energy for cellular work. A specialized membrane lipid called **cardiolipin** helps support this process.

In experimental research, SS-31 interacted with cardiolipin and influenced its relationship with **cytochrome c**, a protein involved in electron transport. Electron transport is part of the process that enables mitochondria to make ATP. Under certain conditions, the cardiolipin–cytochrome c interaction can instead promote damaging oxidative reactions.

SS-31 inhibited this damaging activity while preserving cytochrome c's electron-carrying function. In isolated mitochondrial preparations, it also improved measures of respiration and ATP production. [29]

For patients and families, the significance is that researchers are investigating protection of the energy-producing machinery itself. These findings do not establish that SS-31 increases energy production in the motor neurons of people with ALS.

Evidence From an Injury Model

A separate study examined SS-31 in experimental kidney ischemia, where blood supply is interrupted and then restored. The researchers linked its cardiolipin interactions to preservation of mitochondrial structure and recovery of energy production. [30]

This provides additional support for the mitochondrial mechanism. However, kidney injury differs substantially from progressive motor-neuron disease. Evidence from another organ can help explain a biological action without demonstrating its clinical effectiveness in ALS.

What Has Been Studied Directly in ALS?

Unlike the Semax studies discussed earlier, SS-31 has been investigated in an ALS animal model.

In mice carrying the SOD1-G93A mutation, SS-31 treatment improved motor performance and survival compared with control treatment. Researchers also observed less cell loss and reduced markers of oxidative stress in the lumbar spinal cord. Treatment began early in the animals' lives, before the usual symptomatic stage. [4]

These findings are encouraging preclinical evidence, with important limits. The experiment modeled a particular genetic form of disease. It did not test treatment initiated after a human ALS diagnosis, and it cannot establish whether comparable benefits would occur across different forms or stages of ALS.

Its Proposed Place in the Combined Approach

Within this article's therapeutic hypothesis, SS-31 would be investigated for its capacity to protect mitochondrial function and reduce associated oxidative injury. This could potentially complement Semax's effects on neuronal-support signaling and the Millennium Protocol's proposed hormonal and nutraceutical components.

The connection remains theoretical. The studies discussed here did not evaluate that combination, establish synergy, or demonstrate that improved mitochondrial measurements translate into preserved function in people with ALS.

The essential clinical questions are whether SS-31 reaches the relevant tissues sufficiently, produces meaningful effects after disease onset, and improves outcomes such as daily function, breathing, or survival. Its safety within the proposed combination also requires evaluation.

SS-31 therefore offers a specific, experimentally supported mitochondrial mechanism and an ALS animal-study signal worth investigating. The next step is to determine whether that promise can translate into benefit for patients.

10. MOTS-c: Exploring Cellular Metabolic Adaptation

Protecting a cell involves more than maintaining its energy-producing machinery. Cells must also recognize stress and adjust how they use resources. **MOTS-c**, a peptide containing 16 amino acids, has attracted research interest because it participates in this adaptation.

Its proposed role differs from the membrane-related mechanism discussed for SS-31. MOTS-c is being investigated as a signal connecting mitochondrial activity with broader cellular responses. Whether those effects can benefit people with ALS remains an unanswered clinical question.

Mitochondria Also Send Messages

Mitochondria contain their own genetic material. Research identifying MOTS-c showed that mitochondrial DNA can encode a short peptide with effects on metabolism.

In experimental cells and mice, MOTS-c influenced metabolic pathways involving **AMP-activated protein kinase**, or AMPK, a regulator of cellular energy balance. The investigators also reported effects on insulin sensitivity and protection against diet-associated metabolic disturbances in mice. [31]

These findings established a biological role worth investigating. They did not test ALS, and effects on insulin resistance or body weight should not be assumed to meet the needs of someone with motor-neuron disease.

Helping Cells Respond to Stress

The MOTS-c study cited in the introduction examined communication between mitochondria and the nucleus, where most of a cell's genetic instructions are stored.

Under experimental metabolic stress, MOTS-c moved into the nucleus and influenced the expression of genes involved in adaptation. Its activity included interactions with pathways associated with antioxidant responses. [5]

For patients and families, this can be understood as a form of cellular communication: conditions affecting metabolism can help trigger changes in the instructions a cell uses to respond.

This mechanism provides a reason to investigate resilience under stress. It does not establish that administering MOTS-c produces the same response in human motor neurons, restores damaged neurons, or slows ALS.

Muscle Findings and Their Limits

A later study examined MOTS-c in relation to physical performance and muscle biology. Treatment improved physical performance in mice across several age groups and influenced muscle metabolism and gene expression. The researchers also observed increased naturally occurring MOTS-c following exercise in a small group of healthy men. [32]

These are different kinds of evidence. The human observation showed a response to exercise; it was not a trial demonstrating benefit from administered MOTS-c.

Likewise, improving performance in aging mice does not establish that a peptide can preserve muscle function when the nerve supplying that muscle is degenerating. Supporting muscle metabolism and protecting motor neurons are related research questions, but they are not interchangeable outcomes.

Its Proposed Place in the Combined Approach

Within this article's hypothesis, MOTS-c would be investigated for its potential to influence metabolic adaptation and cellular stress responses. SS-31 would be investigated for mitochondrial membrane protection, while Semax would be examined for neuronal-support and inflammatory signaling.

These proposed roles suggest possible complementarity. The cited studies do not establish synergy, an effective treatment sequence, or clinical benefit from combining the peptides with hormonal replenishment and nutraceuticals.

Before translating this hypothesis into ALS care, researchers would need to determine whether administered MOTS-c reaches relevant tissues, produces useful effects in ALS-specific conditions, and avoids unwanted metabolic consequences. Its interaction with the other proposed interventions also requires testing.

MOTS-c therefore contributes an additional biological question to the search for treatment possibilities: Can improving a cell's response to metabolic stress help preserve function in ALS? The experimental evidence supports asking that question. Demonstrating benefit for patients requires the next steps in research.

11. Bringing the Approaches Together

For a family facing ALS, the appeal of a combined approach is understandable. If several biological processes contribute to neuronal damage, addressing more than one may seem more promising than focusing on a single pathway.

That reasoning provides a starting point for research. The challenge is to determine whether the proposed interventions produce useful effects together, whether those effects reach the cells affected by ALS, and whether they improve daily life or disease outcomes.

A Shared Goal Through Different Biological Targets

The approach explored in this article has a common proposed goal: improve the conditions supporting vulnerable neurons while reducing sources of cellular stress.

Its components address different aspects of that goal:

Component	Proposed contribution	Evidence boundary
Hormonal replenishment	Correct documented deficiencies that may contribute to symptoms or impaired physiological function.	Correcting a deficiency does not establish an effect on ALS progression.
Nutraceuticals	Address selected inflammatory, oxidative, or nutritional targets.	Evidence varies by ingredient, formulation, and clinical setting; the combined protocol has not been validated by the studies reviewed here.
Semax	Influence neurotrophic, inflammatory, and cellular stress signaling.	The cited evidence comes primarily from experimental cerebral ischemia. [3,26–28]
SS-31	Protect mitochondrial membrane function and limit associated oxidative injury.	Mechanistic studies and an ALS mouse study support investigation, without demonstrating human ALS benefit. [4,29,30]
MOTS-c	Influence metabolic adaptation and cellular responses to stress.	The cited studies concern cellular metabolism, muscle biology, and aging rather than clinical ALS treatment. [5,31,32]

The experimental peptide findings provide a rationale for this mapping. They do not establish that the interventions produce these benefits in people with ALS.

What Complementarity Would Mean

Complementarity means that interventions might address different, relevant problems. For example, correcting a documented hormonal deficiency could serve a different purpose from protecting mitochondrial function.

Synergy is a stronger claim: it means that the combined effect exceeds what would be expected from the individual interventions. Demonstrating synergy requires direct comparison. It cannot be inferred because two treatments affect different pathways or because their mechanisms sound compatible.

The proposed combination therefore remains a hypothesis. Its components may have overlapping effects, may fail to reach their intended targets, or may interact in ways that alter benefit or risk.

What the Hypothesis Predicts

A useful therapeutic hypothesis should lead to questions that can be tested. This framework predicts that a carefully selected combination might influence several measurable biological processes and, potentially, improve patient outcomes.

Testing it would require establishing whether the interventions produce their intended effects, whether those changes correspond to better function, and whether the combination is acceptably safe. Comparisons would also be needed to determine whether adding the peptides provides benefit beyond the hormonal and nutraceutical components alone.

Improvements in laboratory measurements would be informative, but the decisive outcomes would concern the person: function, breathing, symptom burden, quality of life, and survival.

Preserving Hope While Evaluating Results

An individual may feel better after an intervention without experiencing a change in ALS progression. Relief of a symptom can still matter greatly. Conversely, a favorable laboratory change may occur without a noticeable clinical benefit.

Both possibilities deserve accurate reporting. Separating symptom improvement, correction of a deficiency, and a change in disease progression makes results more useful to patients, families, and researchers.

This combined framework offers a way to organize treatment questions around biology. Its promise depends on careful testing and transparent measurement. For people living with ALS, the goal is to turn plausible mechanisms into evidence that can guide meaningful decisions.

12. What This Could Mean for Someone Living With ALS

Understanding the biology can help patients and families ask more informed questions. It can also make emerging treatment ideas easier to evaluate. The practical challenge is deciding which possibilities deserve consideration, what outcomes to expect, and how to recognize whether an intervention is helping.

The framework presented in this article offers questions for discussion with an ALS care team. It does not provide a definitive treatment regimen or dosing instructions.

Begin With a Clear Purpose

Every proposed intervention should have an identifiable goal. Correcting a documented hormonal deficiency, improving a troublesome symptom, and attempting to slow ALS progression are different goals requiring different evidence.

Before considering an intervention, patients and clinicians can clarify what it is intended to accomplish and how its effects will be evaluated. This makes subsequent changes easier to interpret.

A person may experience worthwhile symptom relief without a change in disease progression. Recognizing that distinction preserves the value of the improvement while keeping expectations accurate.

Keep Specialized ALS Care at the Center

Exploring additional approaches should occur within coordinated ALS care. In a population-based study, attendance at a multidisciplinary ALS clinic was associated with longer survival than care through general neurology services. Because this was an observational comparison, it cannot establish that clinic attendance alone caused the difference. Nevertheless, it supports the importance of coordinated care. [33]

An ALS team can help assess proposed additions in the context of the patient's existing treatments, respiratory needs, swallowing difficulties, nutritional status, and personal priorities. Sharing a complete list of hormones, supplements, and peptides allows the team to evaluate the whole treatment picture.

Measure What Matters to the Patient

Laboratory results can provide useful information, but they cannot capture the full experience of living with ALS.

One established tool is the **ALS Functional Rating Scale–Revised**, or ALSFRS-R. It evaluates aspects of daily function and includes respiratory assessments. [34] It should be considered alongside clinical examination, respiratory testing, and the patient's own account of symptoms and quality of life.

For any additional intervention, a useful monitoring plan would document the starting condition, the intended benefit, adverse effects, and changes over time. Whenever feasible, avoiding multiple simultaneous changes makes it easier to determine which intervention may be responsible for an effect.

Feeling better matters. Demonstrating a slower rate of decline requires more than a short period of improvement or stability.

Understand the Evidence Before Making a Commitment

The studies reviewed in this article support different levels of confidence. Some describe mechanisms in cells, others report results in animals, and a smaller number examine interventions in people with ALS.

An experimental finding can justify further research without establishing a treatment recommendation. Likewise, evidence for one ingredient cannot validate a combination containing several ingredients.

Patients and families can ask:

- Was this intervention studied in people with ALS?
- Were meaningful clinical outcomes measured?
- What is known about its safety in this setting?
- How will benefit, lack of benefit, or harm be recognized?
- What financial and practical burden will it add?

These questions apply equally to hormonal replenishment, nutraceuticals, and peptides.

The Patient's Priorities Remain Central

People living with ALS should not feel responsible for making an experimental approach succeed. A disappointing outcome does not reflect insufficient effort, commitment, or hope.

Some families will prioritize participation in research. Others will focus on symptom relief, daily comfort, or reducing treatment burden. These are personal decisions that deserve respectful support.

The purpose of this biological framework is to make possibilities more understandable and discussions more informed. Its value depends on helping patients and families make decisions that reflect both the evidence and what matters most in their lives.

Conclusion: Hope Through Understanding and Investigation

ALS brings profound uncertainty into the lives of patients and families. Understanding its biology cannot remove that uncertainty, but it can help identify meaningful questions, evaluate treatment possibilities, and give the search for hope a scientific foundation.

This article has explored how trauma can initiate cellular injury and inflammatory responses, and how persistent inflammation may interact with oxidative stress, impaired mitochondrial function, and neuronal vulnerability. These connections offer a framework for investigation. They do not establish trauma-induced inflammation as the cause of every case of ALS. Genetic causes, protein abnormalities, and differences between vulnerable and resistant neurons remain essential parts of the disease model. [1,2,16–18]

Within this framework, the Millennium Protocol's hormonal and nutraceutical components are proposed as ways to address documented deficiencies and selected inflammatory or oxidative processes. Their effects must be evaluated individually. Correcting a deficiency or relieving a symptom can matter to a patient, while remaining distinct from slowing motor-neuron degeneration.

Semax, SS-31, and MOTS-c introduce additional research possibilities. Semax has influenced neurotrophic and inflammatory signaling in experimental cerebral ischemia. SS-31 has demonstrated mitochondrial effects and encouraging findings in an ALS mouse model. MOTS-c has influenced metabolic adaptation and cellular stress responses. [3–5,26–32] These findings support further investigation; the studies reviewed here do not demonstrate that the proposed combination slows or reverses human ALS.

The next step is to turn this biological rationale into testable research. That requires clear patient selection, careful safety assessment, and measurement of outcomes that matter: daily function, breathing, symptom burden, quality of life, and survival. Laboratory changes can help explain an intervention's activity, but they cannot replace evidence of patient benefit.

For someone living with ALS, hope may include exploring research, treating an additional health problem, preserving independence, or finding greater comfort. Each deserves attention. No patient should feel that the outcome depends on pursuing every possibility or maintaining a particular attitude.

The biology gives us reasons to keep asking questions. Patients and families deserve answers developed through rigorous research, communicated honestly, and applied with compassion.

References

1. **Frakes AE, Ferraiuolo L, Haidet-Phillips AM, et al.** Microglia induce motor neuron death via the classical NF- κ B pathway in amyotrophic lateral sclerosis. *Neuron*. 2014;81(5):1009–1023. DOI: [10.1016/j.neuron.2014.01.013](https://doi.org/10.1016/j.neuron.2014.01.013)
2. **Zhu X, Russell ER, Lyall DM, et al.** Traumatic brain injury and risk of amyotrophic lateral sclerosis. *JAMA Network Open*. 2025;8(10):e2535119. DOI: [10.1001/jamanetworkopen.2025.35119](https://doi.org/10.1001/jamanetworkopen.2025.35119)
Sudarkina OY, Filippenkov IB, Stavchansky VV, et al. Brain protein expression profile confirms the protective effect of the ACTH(4–7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. *International Journal of Molecular Sciences*. 2021;22(12):6179. DOI: [10.3390/ijms22126179](https://doi.org/10.3390/ijms22126179)
3. **Petri S, Kiaei M, Damiano M, et al.** Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. *Journal of Neurochemistry*. 2006;98(4):1141–1148. DOI: [10.1111/j.1471-4159.2006.04018.x](https://doi.org/10.1111/j.1471-4159.2006.04018.x)
4. **Kim KH, Son JM, Benayoun BA, Lee C.** The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. *Cell Metabolism*. 2018;28(3):516–524.e7. DOI: [10.1016/j.cmet.2018.06.008](https://doi.org/10.1016/j.cmet.2018.06.008)
5. **Wolf JA, Stys PK, Lusardi T, Meaney D, Smith DH.** Traumatic axonal injury induces calcium influx modulated by tetrodotoxin-sensitive sodium channels. *Journal of Neuroscience*. 2001;21(6):1923–1930. doi: [10.1523/JNEUROSCI.21-06-01923.2001](https://doi.org/10.1523/JNEUROSCI.21-06-01923.2001). PMID: [11245677](https://pubmed.ncbi.nlm.nih.gov/11245677/). [pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11245677/)
6. **Laird MD, Shields JS, Sukumari-Ramesh S, Kimbler DE, Fessler RD, Shakir B, Youssef P, Yanasak N, Vender JR, Dhandapani KM.** High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. *Glia*. 2014;62(1):26–38. doi: [10.1002/glia.22581](https://doi.org/10.1002/glia.22581). PMID: [24166800](https://pubmed.ncbi.nlm.nih.gov/24166800/). [PubMed](https://pubmed.ncbi.nlm.nih.gov/24166800/)
7. **Yuen TJ, Browne KD, Iwata A, Smith DH.** Sodium channelopathy induced by mild axonal trauma worsens outcome after a repeat injury. *Journal of Neuroscience Research*. 2009;87(16):3620–3625. doi: [10.1002/jnr.22161](https://doi.org/10.1002/jnr.22161). PMID: [19565655](https://pubmed.ncbi.nlm.nih.gov/19565655/). [PMC](https://pubmed.ncbi.nlm.nih.gov/19565655/)
8. **Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W.** Inflammation and white matter degeneration persist for years after a single traumatic brain injury. *Brain*. 2013;136(Pt 1):28–42. doi: [10.1093/brain/aws322](https://doi.org/10.1093/brain/aws322). PMID: [23365092](https://pubmed.ncbi.nlm.nih.gov/23365092/).
9. **Yuen TJ, Browne KD, Iwata A, Smith DH.** Sodium channelopathy induced by mild axonal trauma worsens outcome after a repeat injury. *Journal of Neuroscience Research*. 2009;87(16):3620–3625. doi: [10.1002/jnr.22161](https://doi.org/10.1002/jnr.22161). PMID: [19565655](https://pubmed.ncbi.nlm.nih.gov/19565655/). [PMC](https://pubmed.ncbi.nlm.nih.gov/19565655/)
10. **Loane DJ, Kumar A, Stoica BA, Cabatbat R, Faden AI.** Progressive neurodegeneration after experimental brain trauma: association with chronic microglial activation. *Journal of Neuropathology & Experimental Neurology*. 2014;73(1):14–29. doi: [10.1097/NEN.000000000000021](https://doi.org/10.1097/NEN.000000000000021). PMID: [24335533](https://pubmed.ncbi.nlm.nih.gov/24335533/). [PubMed](https://pubmed.ncbi.nlm.nih.gov/24335533/)
11. **Liddel SA, Gattenplan KA, Clarke LE, et al.** Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*. 2017;541(7638):481–487. doi: [10.1038/nature21029](https://doi.org/10.1038/nature21029). PMID: [28099414](https://pubmed.ncbi.nlm.nih.gov/28099414/). [PubMed](https://pubmed.ncbi.nlm.nih.gov/28099414/)
12. **Ismael S, Nasoohi S, Ishrat T.** MCC950, the selective inhibitor of nucleotide oligomerization domain-like receptor protein-3 inflammasome, protects mice against traumatic brain injury. *Journal of Neurotrauma*. 2018;35(11):1294–1303. doi: [10.1089/neu.2017.5344](https://doi.org/10.1089/neu.2017.5344).

13. **Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncel RW.** Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. *Annals of Neurology*. 1995;38(1):73–84. doi: [10.1002/ana.410380114](https://doi.org/10.1002/ana.410380114).
14. **Cassina P, Cassina A, Pehar M, et al.** Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. *Journal of Neuroscience*. 2008;28(16):4115–4122. doi: [10.1523/JNEUROSCI.5308-07.2008](https://doi.org/10.1523/JNEUROSCI.5308-07.2008).
15. **Bosco DA, Morfini G, Karabacak NM, et al.** Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. *Nature Neuroscience*. 2010;13(11):1396–1403. doi: [10.1038/nn.2660](https://doi.org/10.1038/nn.2660).
16. **Kaplan A, Spiller KJ, Towne C, et al.** Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. *Neuron*. 2014;81(2):333–348. doi: [10.1016/j.neuron.2013.12.009](https://doi.org/10.1016/j.neuron.2013.12.009).
17. **Neumann M, Sampathu DM, Kwong LK, et al.** Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science*. 2006;314(5796):130–133. doi: [10.1126/science.1134108](https://doi.org/10.1126/science.1134108).
18. **Renton AE, Majounie E, Waite A, et al.** A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron*. 2011;72(2):257–268. doi: [10.1016/j.neuron.2011.09.010](https://doi.org/10.1016/j.neuron.2011.09.010).
19. **Watanobe H, Hayakawa Y.** Hypothalamic interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats. *Endocrinology*. 2003;144(11):4868–4875. doi: [10.1210/en.2003-0644](https://doi.org/10.1210/en.2003-0644).
20. **Militello A, Vitello G, Lunetta C, et al.** The serum level of free testosterone is reduced in amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*. 2002;195(1):67–70. doi: [10.1016/S0022-510X\(01\)00688-8](https://doi.org/10.1016/S0022-510X(01)00688-8).
21. **Murugan S, Jakka P, Namani S, Mujumdar V, Radhakrishnan G.** The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation. *Journal of Biological Chemistry*. 2019;294(12):4596–4607. doi: [10.1074/jbc.RA118.005543](https://doi.org/10.1074/jbc.RA118.005543).
22. **Sorenson EJ, Windbank AJ, Mandrekas JN, et al.** Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. *Neurology*. 2008;71(22):1770–1775. doi: [10.1212/01.wnl.0000335970.78664.36](https://doi.org/10.1212/01.wnl.0000335970.78664.36).
23. **Chen X, Wu S, Chen C, et al.** Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-κB pathway following experimental traumatic brain injury. *Journal of Neuroinflammation*. 2017;14:143. doi: [10.1186/s12974-017-0917-3](https://doi.org/10.1186/s12974-017-0917-3).
24. **Kaufmann P, Thompson JLP, Levy G, et al.** Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. *Annals of Neurology*. 2009;66(2):235–244. doi: [10.1002/ana.21743](https://doi.org/10.1002/ana.21743). PMID: [19743457](https://pubmed.ncbi.nlm.nih.gov/19743457/). [PubMed](https://pubmed.ncbi.nlm.nih.gov/19743457/)
25. **Oki R, Izumi Y, Fujita K, et al.** Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: a randomized clinical trial. *JAMA Neurology*. 2022;79(6):575–583. doi: [10.1001/jamaneurol.2022.0901](https://doi.org/10.1001/jamaneurol.2022.0901).
26. **Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV.** Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. *Cellular and Molecular Neurobiology*. 2010;30(1):71–79. doi: [10.1007/s10571-009-9432-0](https://doi.org/10.1007/s10571-009-9432-0). PMID: [19633950](https://pubmed.ncbi.nlm.nih.gov/19633950/). [PubMed](https://pubmed.ncbi.nlm.nih.gov/19633950/)
27. **Dergunova LV, Dmitrieva VG, Filippenkov IB, et al.** [The peptide drug ACTH(4–7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischemia of the rat brain]. *Molekuliarnaya Biologiya (Mosk)*. 2021;55(3):402–411. Russian. doi: [10.31857/S0026898421010043](https://doi.org/10.31857/S0026898421010043).
28. **Medvedeva EV, Dmitrieva VG, Povarova OV, et al.** The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. *BMC Genomics*. 2014;15:228. doi: [10.1186/1471-2164-15-228](https://doi.org/10.1186/1471-2164-15-228).
29. **Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH.** Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. *British Journal of Pharmacology*. 2014;171(8):2017–2028. doi: [10.1111/bph.12468](https://doi.org/10.1111/bph.12468).
30. **Birk AV, Liu S, Soong Y, et al.** The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. *Journal of the American Society of Nephrology*. 2013;24(8):1250–1261. doi: [10.1681/ASN.2012121216](https://doi.org/10.1681/ASN.2012121216).

31. **Lee C, Zeng J, Drew BG, et al.** The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metabolism*. 2015;21(3):443–454. doi: [10.1016/j.cmet.2015.02.009](https://doi.org/10.1016/j.cmet.2015.02.009). PMID: [25738459](https://pubmed.ncbi.nlm.nih.gov/25738459/). [PubMed](#)
32. **Reynolds JC, Lai RW, Woodhead JST, et al.** MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. *Nature Communications*. 2021;12(1):470. doi: [10.1038/s41467-020-20790-0](https://doi.org/10.1038/s41467-020-20790-0). PMID: [33473109](https://pubmed.ncbi.nlm.nih.gov/33473109/).
33. **Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O.** Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. *Journal of Neurology, Neurosurgery & Psychiatry*. 2003;74(9):1258–1261. doi: [10.1136/jnnp.74.9.1258](https://doi.org/10.1136/jnnp.74.9.1258).
34. **Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A; BDNF ALS Study Group (Phase III).** The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. *Journal of the Neurological Sciences*. 1999;169(1–2):13–21. doi: [10.1016/S0022-510X\(99\)00210-5](https://doi.org/10.1016/S0022-510X(99)00210-5).
35. **Gu D, Ou S, Tang M, Yin Z, Wang Z, Liu G.** Trauma and amyotrophic lateral sclerosis: a systematic review and meta-analysis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2021;22(3–4):170–185. doi: [10.1080/21678421.2020.1861024](https://doi.org/10.1080/21678421.2020.1861024).